Editore: Springer, Heidelberg, 2000
Da: PsychoBabel & Skoob Books, Didcot, Regno Unito
EUR 5,36
Quantità: 1 disponibili
Aggiungi al carrelloPaperback. Condizione: Very Good. Paperback journal with very few superficial marks and scores on covers, and lightly worn edges, leading corners and spine ends. Pages are clean and sound throughout; all content is clear. TS. Used.
Da: Antiquariat Thomas Haker GmbH & Co. KG, Berlin, Germania
Membro dell'associazione: GIAQ
Prima edizione
EUR 14,40
Quantità: 1 disponibili
Aggiungi al carrelloHardcover. Condizione: Wie neu. 1st ed. 268 S. Like new. Shrink wrapped. Sprache: Englisch Gewicht in Gramm: 825.
Lingua: Inglese
Editore: Springer-Verlag, Berlin, Germany, 1991
ISBN 10: 3540548599 ISBN 13: 9783540548591
Da: 100POCKETS, Berkeley, CA, U.S.A.
Hardcover. Condizione: Near Fine. HARD COVER. Text/BRAND NEW & Bright. Black cloth boards/Fine. DJ/None (as Issued?). PO name to first title page. Schering Foundation Workshop 3, June 27-28, 1911, Berlin symposium. Mechanisms through which glutamate, the principal excitatory neurotransmitter in the mammalian central nervous system, modifies neuronal membrane functions and intraneuronal functions. 186 pgs. 12 chapters. Essays review conceptual approaches and experiments reference to links between excitation mediated by glutamate and second messenger systems.
Da: Revaluation Books, Exeter, Regno Unito
EUR 339,86
Quantità: 2 disponibili
Aggiungi al carrelloHardcover. Condizione: Brand New. 1st edition. 255 pages. 9.25x6.50x0.75 inches. In Stock.
Da: AHA-BUCH GmbH, Einbeck, Germania
EUR 310,84
Quantità: 1 disponibili
Aggiungi al carrelloBuch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Today, biologists and medicinal chemists realize that there is a strong relationship between pharmacodynamic (what the drug does to the organism) and pharmacokinetic (what the organism does to the drug) effects. A significant contributing factor to the evolution in drug discovery was the methodological and technological revolution with the advent of combinatorial chemistry, high-throughput screening and profiling, and in silico prediction of target-based activity and ADMET (absorption, distribution, metabolism, excretion and toxicity) properties. High-throughput screening and in silico methods have accelerated the process towards drugability of new chemical structures. Another component of the revolution in drug discovery is the replacement of the disease (indication)-based approach by a target-based approach. A better understanding of pathophysiology of diseases and the underlying biological processes of diseases combined with explosive development of genomics and proteomics have been instrumental in the birth of this new paradigm. This volume summarizes discussions of these three aspects of modern drug discovery, i.e. priority for targets, early ADMET assessment, and in silico screening. We trust that readers from academia as well as from industry will benefit from these studies.